01—Abstract
Summary
Summary of the 10-Q filed May 2, 2024. Cited figures are marked; the original filing is the authoritative source.
Zoetis Inc. reported strong financial results for the first quarter of 2024, with total revenue increasing by 10% to $2.19 billiona compared to the same period in 2023.
This growth was driven by a solid 12% increase on an operational basis, primarily attributed to price increases (7%), new product volume (4%), and key dermatology product volume (3%). Net income attributable to Zoetis Inc. rose by 9% to $599 millionb, with diluted earnings per share increasing from $1.19 to $1.31. The company's performance highlights the strength and resilience of the animal health market, with notable growth in companion animal products, particularly in the U.S. segment.
The International segment also showed positive operational growth despite currency headwinds. Zoetis continues to invest in research and development to fuel future innovation and maintain its market leadership.
02—Key points
Key Highlights
- Total revenue increased by 10% to $2.19 billion for Q1 2024, up from $2.00 billion in Q1 2023.
- Operational revenue growth was strong at 12%, driven by price increases, new product volume, and growth in key dermatology products.
- Net income attributable to Zoetis Inc. increased by 9% to $599 million ($0.37 billion).
- Diluted earnings per share (EPS) grew to $1.31 from $1.19 in the prior year period, a 10% increase.
- The U.S. segment revenue saw a significant 16% increase, largely driven by strong performance in companion animal products.
- The International segment's operational revenue increased by 8%, demonstrating global demand despite unfavorable foreign exchange impacts.
- Research and Development expenses increased by 14% to $162 million, reflecting continued investment in innovation.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 2, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $2.19B$2.00B | +9.5% |
| Cost of Revenue | $643.00M$588.00M | +9.4% |
| Gross Profit | $1.55B$1.41B | +9.6% |
| SG&A Expenses | $547.00M$505.00M | +8.3% |
| Interest Expense | $58.00M$63.00M | −7.9% |
| Net Income | $599.00M$551.00M | +8.7% |
| EPS (Basic) | $1.31$1.19 | +10.1% |
| EPS (Diluted) | $1.31$1.19 | +10.1% |
| Shares Outstanding (Basic) | 458.00M463.50M | −1.2% |
| Shares Outstanding (Diluted) | 458.80M464.60M | −1.2% |
05—Questions
Frequently Asked Questions
What were the main drivers of Zoetis' revenue growth in the first quarter of 2024?
Zoetis' revenue growth was primarily driven by a combination of price increases (approximately 7%), volume growth from new products (approximately 4%), and increased volume from key dermatology products (approximately 3%). Operational revenue growth was 12%, which was partially offset by a 2% negative impact from foreign exchange.
How did the U.S. and International segments perform?
The U.S. segment showed robust growth with revenue increasing by 16% to $1.16 billion, primarily due to strong companion animal product sales. The International segment's revenue increased by 3% overall, but on an operational basis, it grew by 8%, driven by companion animal products, despite a 5% negative impact from foreign exchange.
What is Zoetis' stance on share repurchases and dividends?
Zoetis has an ongoing share repurchase program. As of March 31, 2024, there was $1.2 billion remaining under a $3.5 billion authorization. The company also declared dividends of $0.432 per share in the first quarter of 2024, up from $0.375 per share in the prior year, indicating a commitment to returning capital to shareholders.
How is Zoetis managing its expenses?
While revenue grew, cost of sales as a percentage of revenue remained stable at 29.4%. Selling, general, and administrative (SG&A) expenses increased by 8%, reflecting investments in compensation, advertising, and technology. Research and development (R&D) expenses saw a 14% increase to $162 million, signaling continued investment in future growth and innovation.
06—Continue